Physical outcome (logistic regression) | Cognitive outcome (linear regression) | |||||
OR | R2 | p Value† | Slope | R2 | p Value† | |
Baseline variables | ||||||
Baseline EDSS | 2.07 | 0.22 | <0.0001 | –1.12 | 0.12 | <0.0001 |
MSSS at trial onset | 1.23 | 0.07 | 0.0004 | –0.25 | 0.02 | 0.09 |
Baseline MRI T2 BOD (cm2) | 1.03 | 0.07 | 0.001 | –0.11 | 0.21 | <0.0001 |
Duration of MS (y) | 1.07 | 0.05 | 0.003 | –0.15 | 0.05 | 0.004 |
Third ventricular width (mm) | 1.18 | 0.04 | 0.011 | –0.94 | 0.21 | <0.0001 |
Age at trial start | 1.03 | 0.01 | NS | –0.19 | 0.00 | NS |
Age at MS onset | 0.98 | 0.01 | NS | 0.12 | 0.04 | 0.02 |
Annual relapse rate prior to trial (2 years) | 1.11 | 0.00 | NS | 0.07 | 0.00 | NS |
Premorbid IQ | 0.99 | 0.00 | NS | 0.18 | 0.14 | <0.0001 |
Gender | 0.91 | 0.00 | NS | 0.77 | 0.00 | NS |
On-RCT variables | ||||||
Annual relapse rate | 1.82 | 0.12 | <0.0001 | –0.47 | 0.02 | NS |
Actual EDSS change—baseline to 2 years | 1.59 | 0.11 | <0.0001 | –0.32 | 0.01 | NS |
Categorical EDSS change (≥1 point) | 2.71 | 0.06 | 0.002 | –1.68 | 0.02 | 0.05 |
Confirmed 1 point EDSS progression | 1.84 | 0.02 | 0.05 | 0.81 | 0.00 | NS |
Change, third ventricular width (mm) | 1.06 | 0.00 | NS | –1.27 | 0.07 | 0.003 |
50 μg treatment group during RCT‡ | 0.74 | 0.01 | NS | 1.42 | 0.02 | 0.09 |
250 μg treatment group during RCT‡ | 1.07 | 0.01 | NS | 1.41 | 0.02 | 0.09 |
Total IFNβ-1b exposure (years) (on LTF) | 0.98 | 0.00 | NS | –0.08 | 0.01 | NS |
No of new T2 lesions | 0.96 | 0.01 | NS | –0.10 | 0.01 | NS |
NAbs (≥20 NU/ml) | 0.83 | 0.00 | NS | –0.49 | 0.00 | NS |
Change, MRI T2 BOD (cm2) | 1.01 | 0.00 | NS | –0.01 | 0.01 | NS |
↵* Physical outcome=either SPMS or EDSS=6; cognitive outcome=Cognitive Performance Index (see text).
↵† NS=p>0.1.
↵‡ Comparison versus placebo.
BOD, burden of disease; EDSS, Expanded Disability Status Scale score; IFNβ, interferon β; MS, multiple sclerosis; MSSS, Multiple Sclerosis Severity Score; NAbs, neutralising antibodies; RCT, randomised controlled trial; SPMS, secondary progressive multiple sclerosis.